Idarubicin is named as an intervention in 5 current clinical trials in our China, USA and UK registers. 2 are recruiting patients now. The most common phase is Phase 1. The sponsor with the most trials is Janssen Research & Development, LLC (1). The most-studied condition is AML, Adult.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT06001788 · ClinicalTrials.gov ↗ · AML, AML With Mutated NPM1, Hematologic Malignancy
|
Phase 1 | Recruiting | Kura Oncology, Inc. | USA |
|
MRD-positive AML Clinical Study
NCT07131059 · ClinicalTrials.gov ↗ · AML, Adult
|
Not applicable | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | China |
|
Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML
NCT07486479 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia (AML)
|
Phase 3 | Not yet open | The First Affiliated Hospital of Soochow University | China |
|
Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML
NCT05177731 · ClinicalTrials.gov ↗ · AML, Adult, Chemotherapy Effect
|
Phase 3 | Active, closed | Chen Suning | China |
|
A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
NCT05453903 · ClinicalTrials.gov ↗ · Leukemia, Myeloid, Acute
|
Phase 1 | Active, closed | Janssen Research & Development, LLC | UK, USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Janssen Research & Development, LLC | 1 |
| Kura Oncology, Inc. | 1 |
| The First Affiliated Hospital of Soochow University | 1 |
| Chen Suning | 1 |
| Institute of Hematology & Blood Diseases Hospital, China | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 3 | 1 |
| Clinical trials in USA | 2 | 1 |
| Clinical trials in UK | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
5 current trials in our China, USA and UK registers name Idarubicin as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 5 trials are recruiting: 1 with sites in China and 1 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Janssen Research & Development, LLC (1), Kura Oncology, Inc (1), The First Affiliated Hospital of Soochow University (1) and Chen Suning (1), among 5 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Idarubicin works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Idarubicin works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Idarubicin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.